Dejima, Hitoshi
Hu, Xin
Chen, Runzhe
Zhang, Jiexin http://orcid.org/0000-0001-9526-6730
Fujimoto, Junya
Parra, Edwin R. http://orcid.org/0000-0001-9068-1636
Haymaker, Cara http://orcid.org/0000-0002-1317-9287
Hubert, Shawna M. http://orcid.org/0000-0002-7907-9609
Duose, Dzifa
Solis, Luisa M. http://orcid.org/0000-0002-1253-630X
Su, Dan http://orcid.org/0000-0002-8423-1994
Fukuoka, Junya
Tabata, Kazuhiro
Pham, Hoa H. N. http://orcid.org/0000-0002-0998-4486
Mcgranahan, Nicholas
Zhang, Baili
Ye, Jie
Ying, Lisha
Little, Latasha
Gumbs, Curtis
Chow, Chi-Wan
Estecio, Marcos Roberto
Godoy, Myrna C. B.
Antonoff, Mara B. http://orcid.org/0000-0001-6247-9537
Sepesi, Boris
Pass, Harvey I.
Behrens, Carmen
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Vaporciyan, Ara A.
Heymach, John V. http://orcid.org/0000-0001-9068-8942
Scheet, Paul
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Wu, Jia http://orcid.org/0000-0001-8392-8338
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Reuben, Alexandre http://orcid.org/0000-0003-4510-0382
Kadara, Humam
Wistuba, Ignacio I.
Zhang, Jianjun http://orcid.org/0000-0001-7872-3477
Article History
Received: 7 September 2020
Accepted: 31 March 2021
First Online: 11 May 2021
Competing interests
: J.J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. I.I.W reports Honoraria from Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Oncocyte, Flame, and MSD; Research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. H.K. reports funding to MD Anderson Cancer Center from Johnson and Johnson. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. The other authors declare no competing interests.